XML 14 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 2,143 $ 2,801
Accounts receivables, net of allowance for credit losses of $88 million and $91 million as of March 31, 2023 and December 31, 2022 3,435 3,696
Inventories 4,118 3,833
Prepaid expenses 1,253 1,162
Other current assets 542 549
Assets held for sale 10 10
Total current assets 11,501 12,051
Deferred income taxes 1,572 1,453
Other non-current assets 450 441
Property, plant and equipment, net 5,751 5,739
Operating lease right-of-use assets 420 419
Identifiable intangible assets, net 5,964 6,270
Goodwill [1] 17,799 17,633
Total assets 43,456 44,006
Current liabilities:    
Short-term debt 1,023 2,109
Sales reserves and allowances 3,309 3,750
Accounts payables 2,381 1,887
Employee-related obligations 432 566
Accrued expenses 2,267 2,151
Other current liabilities 1,000 1,005
Total current liabilities 10,411 11,469
Long-term liabilities:    
Deferred income taxes 550 548
Other taxes and long-term liabilities 3,869 3,847
Senior notes and loans 19,668 19,103
Operating lease liabilities 345 349
Total long-term liabilities 24,433 23,846
Commitments and contingencies, see note 10
Total liabilities 34,844 35,315
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; March 31, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,226 million shares and 1,217 million shares, respectively 57 57
Additional paid-in capital 27,719 27,688
Accumulated deficit (13,086) (12,882)
Accumulated other comprehensive loss (2,701) (2,838)
Treasury shares as of March 31, 2023 and December 31, 2022: 106 million ordinary shares (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 7,860 7,897
Non-controlling interests 751 794
Total equity 8,612 8,691
Total liabilities and equity $ 43,456 $ 44,006
[1] Accumulated goodwill impairment as of March 31, 2023 and December 31, 2022 was approximately $27.6 billion.